Although single case and prove‐of‐concept studies have suggested that immunotherapeutic approaches can be successful in BCC [27, 28], very little is known about how oncogenic HH/GLI signaling regulates tumor immunity in this cancer entity. This evidence concerns the gene GLI1 and neoplasm.